BridgeBio's Promising Biotech Pipeline Highlighted by William Blair
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 23 hours ago
0mins
Should l Buy BBIO?
Source: Benzinga
- Unique Market Position: Analyst John Boyle highlights BridgeBio's unique position with the accelerating launch of Attruby and near-term NDA submissions, setting the stage for late-2026/early-2027 launches in the rare genetic disease treatment market.
- Product Competitive Edge: Market surveys indicate that prescribers view both Attruby and Amvuttra as superior to Pfizer's Tafamidis, which has approximately $6 billion in annual sales, suggesting that BridgeBio's products are gaining traction in clinical applications.
- Sales Forecast and Risks: The analyst models U.S. sales of Attruby reaching $3.4 billion by 2035, while acknowledging potential generic entry risks in late 2028; however, Attruby's strong TTR stabilization and simple twice-daily dosing could justify premium pricing.
- Other Market Opportunities: BridgeBio also sees significant market opportunities with other rare disease drugs, particularly infigratinib for achondroplasia and encaleret for autosomal dominant hypocalcemia type 1, with the latter achieving its primary endpoint in the CALIBRATE Phase 3 study in October 2025, indicating strong future prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BBIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BBIO
Wall Street analysts forecast BBIO stock price to rise
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 74.320
Low
85.00
Averages
98.50
High
157.00
Current: 74.320
Low
85.00
Averages
98.50
High
157.00
About BBIO
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BridgeBio Presents Positive Interim Data for BBP-418 in LGMD2I/R9
- Clinical Trial Results: BridgeBio presented positive interim analysis results for BBP-418 at the MDA conference, highlighting early separation from placebo in the 100-meter timed test, with improvements evident as early as three months, indicating the drug's rapid onset of action.
- FDA Submission Plans: Following the positive interim results, BridgeBio intends to submit a New Drug Application (NDA) to the FDA in the first half of 2026, with a U.S. launch anticipated in late 2026 to early 2027, potentially making it the first approved therapy for LGMD2I/R9, which holds significant market potential.
- Safety Analysis: BBP-418 demonstrated a safety profile comparable to placebo, with 93.2% of patients reporting treatment-emergent adverse events, and similar rates of serious adverse events, indicating good tolerability and laying a foundation for future clinical use.
- Efficacy Sustainability: Among patients treated with BBP-418 for 12 months, 59.6% achieved significant reductions in serum creatine kinase (CK) levels, and 38.3% normalized CK levels, demonstrating the drug's sustained efficacy in improving muscle function, which could transform the treatment landscape for LGMD2I/R9.
See More
BridgeBio Pharma Stock Soars on Price Target Upgrade
- Stock Surge: BridgeBio Pharma's shares jumped 13.22% on Tuesday, closing at $74.32, driven by a double-digit price target upgrade from an investment firm, indicating strong market confidence in its future performance.
- Price Target Increase: JPMorgan raised BridgeBio's price target from $89 to $94, representing a 26% upside potential from its latest closing price, further solidifying its 'overweight' rating and reflecting analysts' optimism about the company's prospects.
- Clinical Trial Data: At the MDA Clinical and Scientific Conference in Orlando, Florida, BridgeBio presented data from its third-phase clinical trial for BBP-418 in patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), showing a statistically significant 2.6-point improvement in NSAD compared to placebo, indicating the therapy's efficacy.
- FDA Recommendation: The company stated that the FDA recommended pursuing traditional approval for BBP-418, with plans to submit a new drug application in the first half of the year and an expected official launch later this year or early 2027, marking a significant advancement in its treatment pipeline.
See More
U.S. Markets Closed with Mixed Results on Tuesday, Driven by BridgeBio Pharma's Gains and Centene's Declines
- U.S. Stock Market Performance: U.S. stock indexes closed mixed on Tuesday, with overall performance remaining flat.
- Index Movements: The Dow Jones Industrial Average dropped by 0.07%, while the S&P 500 fell by 0.21%.
See More
BridgeBio's Promising Biotech Pipeline Highlighted by William Blair
- Unique Market Position: Analyst John Boyle highlights BridgeBio's unique position with the accelerating launch of Attruby and near-term NDA submissions, setting the stage for late-2026/early-2027 launches in the rare genetic disease treatment market.
- Product Competitive Edge: Market surveys indicate that prescribers view both Attruby and Amvuttra as superior to Pfizer's Tafamidis, which has approximately $6 billion in annual sales, suggesting that BridgeBio's products are gaining traction in clinical applications.
- Sales Forecast and Risks: The analyst models U.S. sales of Attruby reaching $3.4 billion by 2035, while acknowledging potential generic entry risks in late 2028; however, Attruby's strong TTR stabilization and simple twice-daily dosing could justify premium pricing.
- Other Market Opportunities: BridgeBio also sees significant market opportunities with other rare disease drugs, particularly infigratinib for achondroplasia and encaleret for autosomal dominant hypocalcemia type 1, with the latter achieving its primary endpoint in the CALIBRATE Phase 3 study in October 2025, indicating strong future prospects.
See More
BridgeBio Presents Interim Data for BBP-418 at MDA Conference
- Clinical Trial Progress: BridgeBio Pharma will present interim analysis data for BBP-418 targeting limb-girdle muscular dystrophy type 2I/R9 at the Muscular Dystrophy Association conference on March 10-11, 2026, highlighting the drug's potential in treating rare genetic diseases.
- Academic Collaboration Showcase: Academic collaborators from Yale School of Medicine will present an oral session on March 11, 2026, discussing a high-throughput assay for measuring ribitol response across FKRP variants, further supporting BBP-418's research.
- Poster Presentation Topics: On March 10, 2026, BridgeBio will feature four posters covering disease burden, treatment patterns, healthcare resource utilization, and long-term survival modeling, showcasing the translational journey of BBP-418 from pathophysiology to registrational trials.
- Market Performance: BBIO's stock has traded between $28.33 and $84.94 over the past year, closing at $66.54, up 3.11%, indicating positive market sentiment towards its research advancements.
See More
BridgeBio Pharma Q4 2025 Earnings Call Insights
- Strong Financial Performance: BridgeBio reported total revenues of $154.2 million in Q4 2025, with net product revenue from Attruby reaching $146.2 million, a significant increase from $5.9 million in the same period last year, indicating robust market performance and product acceptance.
- Optimistic Future Outlook: Management expects to achieve over $600 million in profit by 2028, primarily driven by four late-stage Phase III assets, signaling a transition to positive cash flow and enhancing future financial stability.
- Product Launch Readiness: CEO Kumar emphasized that market launches for encaleret and BBP-418 are anticipated in late 2026 or early 2027, reflecting proactive preparations for new product introductions aimed at further expanding market share.
- Competitive Risk Management: Despite stock volatility due to tafamidis IP issues, management remains confident in Attruby's market positioning, highlighting that differentiated clinical data will be a key advantage in future competition.
See More
BridgeBio Presents Positive Interim Data for BBP-418 in LGMD2I/R9
- Clinical Trial Results: BridgeBio presented positive interim analysis results for BBP-418 at the MDA conference, highlighting early separation from placebo in the 100-meter timed test, with improvements evident as early as three months, indicating the drug's rapid onset of action.
- FDA Submission Plans: Following the positive interim results, BridgeBio intends to submit a New Drug Application (NDA) to the FDA in the first half of 2026, with a U.S. launch anticipated in late 2026 to early 2027, potentially making it the first approved therapy for LGMD2I/R9, which holds significant market potential.
- Safety Analysis: BBP-418 demonstrated a safety profile comparable to placebo, with 93.2% of patients reporting treatment-emergent adverse events, and similar rates of serious adverse events, indicating good tolerability and laying a foundation for future clinical use.
- Efficacy Sustainability: Among patients treated with BBP-418 for 12 months, 59.6% achieved significant reductions in serum creatine kinase (CK) levels, and 38.3% normalized CK levels, demonstrating the drug's sustained efficacy in improving muscle function, which could transform the treatment landscape for LGMD2I/R9.
See More
BridgeBio Pharma Stock Soars on Price Target Upgrade
- Stock Surge: BridgeBio Pharma's shares jumped 13.22% on Tuesday, closing at $74.32, driven by a double-digit price target upgrade from an investment firm, indicating strong market confidence in its future performance.
- Price Target Increase: JPMorgan raised BridgeBio's price target from $89 to $94, representing a 26% upside potential from its latest closing price, further solidifying its 'overweight' rating and reflecting analysts' optimism about the company's prospects.
- Clinical Trial Data: At the MDA Clinical and Scientific Conference in Orlando, Florida, BridgeBio presented data from its third-phase clinical trial for BBP-418 in patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), showing a statistically significant 2.6-point improvement in NSAD compared to placebo, indicating the therapy's efficacy.
- FDA Recommendation: The company stated that the FDA recommended pursuing traditional approval for BBP-418, with plans to submit a new drug application in the first half of the year and an expected official launch later this year or early 2027, marking a significant advancement in its treatment pipeline.
See More
U.S. Markets Closed with Mixed Results on Tuesday, Driven by BridgeBio Pharma's Gains and Centene's Declines
- U.S. Stock Market Performance: U.S. stock indexes closed mixed on Tuesday, with overall performance remaining flat.
- Index Movements: The Dow Jones Industrial Average dropped by 0.07%, while the S&P 500 fell by 0.21%.
See More
BridgeBio's Promising Biotech Pipeline Highlighted by William Blair
- Unique Market Position: Analyst John Boyle highlights BridgeBio's unique position with the accelerating launch of Attruby and near-term NDA submissions, setting the stage for late-2026/early-2027 launches in the rare genetic disease treatment market.
- Product Competitive Edge: Market surveys indicate that prescribers view both Attruby and Amvuttra as superior to Pfizer's Tafamidis, which has approximately $6 billion in annual sales, suggesting that BridgeBio's products are gaining traction in clinical applications.
- Sales Forecast and Risks: The analyst models U.S. sales of Attruby reaching $3.4 billion by 2035, while acknowledging potential generic entry risks in late 2028; however, Attruby's strong TTR stabilization and simple twice-daily dosing could justify premium pricing.
- Other Market Opportunities: BridgeBio also sees significant market opportunities with other rare disease drugs, particularly infigratinib for achondroplasia and encaleret for autosomal dominant hypocalcemia type 1, with the latter achieving its primary endpoint in the CALIBRATE Phase 3 study in October 2025, indicating strong future prospects.
See More
BridgeBio Presents Interim Data for BBP-418 at MDA Conference
- Clinical Trial Progress: BridgeBio Pharma will present interim analysis data for BBP-418 targeting limb-girdle muscular dystrophy type 2I/R9 at the Muscular Dystrophy Association conference on March 10-11, 2026, highlighting the drug's potential in treating rare genetic diseases.
- Academic Collaboration Showcase: Academic collaborators from Yale School of Medicine will present an oral session on March 11, 2026, discussing a high-throughput assay for measuring ribitol response across FKRP variants, further supporting BBP-418's research.
- Poster Presentation Topics: On March 10, 2026, BridgeBio will feature four posters covering disease burden, treatment patterns, healthcare resource utilization, and long-term survival modeling, showcasing the translational journey of BBP-418 from pathophysiology to registrational trials.
- Market Performance: BBIO's stock has traded between $28.33 and $84.94 over the past year, closing at $66.54, up 3.11%, indicating positive market sentiment towards its research advancements.
See More
BridgeBio Pharma Q4 2025 Earnings Call Insights
- Strong Financial Performance: BridgeBio reported total revenues of $154.2 million in Q4 2025, with net product revenue from Attruby reaching $146.2 million, a significant increase from $5.9 million in the same period last year, indicating robust market performance and product acceptance.
- Optimistic Future Outlook: Management expects to achieve over $600 million in profit by 2028, primarily driven by four late-stage Phase III assets, signaling a transition to positive cash flow and enhancing future financial stability.
- Product Launch Readiness: CEO Kumar emphasized that market launches for encaleret and BBP-418 are anticipated in late 2026 or early 2027, reflecting proactive preparations for new product introductions aimed at further expanding market share.
- Competitive Risk Management: Despite stock volatility due to tafamidis IP issues, management remains confident in Attruby's market positioning, highlighting that differentiated clinical data will be a key advantage in future competition.
See More
